Patents by Inventor Tao Sai

Tao Sai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240216430
    Abstract: Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.
    Type: Application
    Filed: November 28, 2023
    Publication date: July 4, 2024
    Inventors: Zhe LI, Siler PANOWSKI, Barbra Johnson SASU, Bryan A. SMITH, Thomas John VAN BLARCOM, Tao SAI, Guoyun ZHU
  • Patent number: 11987634
    Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: May 21, 2024
    Assignee: PFIZER INC.
    Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
  • Publication number: 20240101710
    Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BCMA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 28, 2024
    Inventors: Zea Melton, Tao Sai, Thomas John Van Blarcom
  • Publication number: 20240067752
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Application
    Filed: September 26, 2023
    Publication date: February 29, 2024
    Inventors: Robert F. KELLEY, Daniel K. KIRCHHOFER, Joyce LAI, Chingwei V. LEE, Wei-Ching LIANG, Michael T. LIPARI, Kelly M. LOYET, Tao SAI, Menno VAN LOOKEREN CAMPAGNE, Yan WU, Germaine FUH
  • Publication number: 20230383008
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Application
    Filed: October 21, 2022
    Publication date: November 30, 2023
    Inventors: Robert F. KELLEY, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • Patent number: 11732041
    Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 22, 2023
    Assignee: ALLOGENE THERAPEUTICS, INC.
    Inventors: Thomas Charles Pertel, Barbra Johnson Sasu, Tao Sai
  • Publication number: 20230041456
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Application
    Filed: June 17, 2022
    Publication date: February 9, 2023
    Inventors: Surabhi SRIVATSA SRINIVASAN, Niranjana NAGARAJAN, Siler PANOWSKI, Yoon PARK, Tao SAI, Barbra SASU, Thomas VAN BLARCOM, Mathilde DUSSEAUX, Roman GALETTO
  • Publication number: 20230002498
    Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
    Type: Application
    Filed: June 1, 2022
    Publication date: January 5, 2023
    Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
  • Patent number: 11512143
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: November 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • Patent number: 11396551
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Surabhi Srivatsa Srinivasan, Niranjana Aditi Nagarajan, Siler Panowski, Yoon Park, Tao Sai, Barbra Johnson Sasu, Thomas John Van Blarcom, Mathilde Brunnhilde Dusseaux, Roman Ariel Galetto
  • Patent number: 11377500
    Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 5, 2022
    Assignee: Pfizer Inc.
    Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
  • Publication number: 20200331998
    Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Inventors: Thomas Charles PERTEL, Barbra Johnson SASU, Tao SAI
  • Publication number: 20190375856
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 12, 2019
    Inventors: Robert F. KELLEY, Daniel K. KIRCHHOFER, Joyce LAI, Chingwei V. LEE, Wei-Ching LIANG, Michael T. LIPARI, Kelly M. LOYET, Tao SAI, Menno VAN LOOKEREN CAMPAGNE, Yan WU, Germaine FUH
  • Patent number: 10421821
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 24, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • Patent number: 10421822
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: September 24, 2019
    Assignee: Genetech, Inc.
    Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • Publication number: 20190233528
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Applicant: Pfizer Inc.
    Inventors: Surabhi Srivatsa Srinivasan, Niranjana Aditi Nagarajan, Siler Panowski, Yoon Park, Tao Sai, Barbra Johnson SASU, Thomas John Van Blarcom, Mathilde Brunnhilde Dusseaux, Roman Ariel Galetto
  • Publication number: 20190233529
    Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Applicant: Pfizer Inc.
    Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
  • Patent number: 10364284
    Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 30, 2019
    Assignee: Eisai, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Publication number: 20190048097
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 14, 2019
    Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • Publication number: 20180094048
    Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Application
    Filed: December 12, 2017
    Publication date: April 5, 2018
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai